Endocrine Abstracts

Introduction: In cancer patients treated with immune checkpoint-inhibitors (ICI) that target CTLA-4, PD-1 and/or PD-L-1, thyroid dysfunction represents the commonest associated endocrinopathy (1). Patients receiving ICI should be monitored for thyroid dysfunction. A case of PD-1 inhibitor-induced thyroid function test (TFT) interference has been reported (2) and having noted discordant results, we undertook a preliminary assessment of the extent of such ICI-related TFT interfe...